Detalles de la búsqueda
1.
Biphenotypic lung carcinoma with coexpression of TTF-1 and ΔNP63/P40 within most of the same individual cells: a further case confirming poor prognosis and a review of literature.
Pathologica
; 116(1): 13-21, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38482671
2.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
3.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Acta Oncol
; 59(9): 1058-1063, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762415
4.
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
Future Oncol
; 15(23): 2743-2757, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339060
5.
Treatment of lung large cell neuroendocrine carcinoma.
Tumour Biol
; 37(6): 7047-57, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26943800
6.
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Tumour Biol
; 37(10): 12991-13003, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27460087
7.
Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Oncology
; 89(4): 227-34, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26066774
8.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 25(3): 233-243.e8, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105153
9.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Clin Lung Cancer
; 25(2): 190-195, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262770
10.
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity.
Cancer Res
; 83(14): 2283-2296, 2023 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37205627
11.
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.
JTO Clin Res Rep
; 4(11): 100555, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38047274
12.
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review.
Expert Rev Respir Med
; 17(9): 787-803, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37817448
13.
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study.
Crit Rev Oncol Hematol
; 187: 104016, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37156405
14.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Clin Lung Cancer
; 24(7): 631-640.e2, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775370
15.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer
; 186: 107417, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918061
16.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
J Thorac Oncol
; 18(8): 1070-1081, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37094664
17.
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Biochim Biophys Acta Rev Cancer
; 1877(6): 188810, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36202311
18.
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Front Immunol
; 13: 987639, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36203609
19.
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(7): e489-e499, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35948460
20.
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Clin Lung Cancer
; 23(1): e17-e28, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34334296